東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Challenges and opportunities of mRNA...

Mueller, Siguna.

FindBook

Google Book

Amazon

博客來

Challenges and opportunities of mRNA vaccines against SARS-CoV-2 = a multidisciplinary perspective /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Challenges and opportunities of mRNA vaccines against SARS-CoV-2/ by Siguna Mueller.
其他題名:	a multidisciplinary perspective /
作者:	Mueller, Siguna.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	xxxii, 439 p. :ill. (chiefly color), digital ;24 cm.
內容註:	Chapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion.
Contained By:	Springer Nature eBook
標題:	COVID-19 vaccines. -
電子資源:	https://doi.org/10.1007/978-3-031-18903-6
ISBN:	9783031189036

Challenges and opportunities of mRNA vaccines against SARS-CoV-2 = a multidisciplinary perspective /
Mueller, Siguna.

Challenges and opportunities of mRNA vaccines against SARS-CoV-2a multidisciplinary perspective /[electronic resource] :by Siguna Mueller. - Cham :Springer International Publishing :2023. - xxxii, 439 p. :ill. (chiefly color), digital ;24 cm.

Chapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion.

This book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy. This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general.

ISBN: 9783031189036

Standard No.: 10.1007/978-3-031-18903-6doiSubjects--Topical Terms:

3625301
COVID-19 vaccines.

LC Class. No.: QR189.5.C68

Dewey Class. No.: 615.372

Challenges and opportunities of mRNA vaccines against SARS-CoV-2 = a multidisciplinary perspective /
LDR:02932nmm a2200325 a 4500 001 2315340
003 DE-He213
005 20230104205645.0
006 m d
007 cr nn 008maaau
008 230902s2023 sz s 0 eng d
020 $a 9783031189036 $q (electronic bk.)
020 $a 9783031189029 $q (paper)
024 7 $a 10.1007/978-3-031-18903-6 $2 doi
035 $a 978-3-031-18903-6
040 $a GP $c GP
041 0 $a eng
050 4 $a QR189.5.C68
072 7 $a PSGL $2 bicssc
072 7 $a MED052000 $2 bisacsh
072 7 $a PSG $2 thema
082 0 4 $a 615.372 $2 23
090 $a QR189.5.C68 $b M947 2023
100 1 $a Mueller, Siguna. $3 3627635
245 1 0 $a Challenges and opportunities of mRNA vaccines against SARS-CoV-2 $h [electronic resource] : $b a multidisciplinary perspective / $c by Siguna Mueller.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xxxii, 439 p. : $b ill. (chiefly color), digital ; $c 24 cm.
505 0 $a Chapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion.
520 $a This book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy. This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general.
650 0 $a COVID-19 vaccines. $3 3625301
650 1 4 $a Virology. $3 642304
650 2 4 $a Medical Microbiology. $3 890951
650 2 4 $a Biotechnology. $3 571461
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-18903-6
950 $a Biomedical and Life Sciences (SpringerNature-11642)